** Shares of Abbott India Ltd ABOT.NS climb 4.4% to 29,030
rupees
** JP Morgan ("overweight") lifts PT on stock to 34,000
rupees from 31,500 rupees, a Street-high, as per data compiled
by LSEG
** Drugmaker's Q3 consol net profit jumped 16% Y/Y on
Wednesday, stock jumped ~4%
** ABOT benefitted from its unique strategy of tailoring
product launches to fit local markets, says JPM
** Adds, strong demand for Rybelsus, oral version of Novo
Nordisk's NOVOb.CO weight-loss drug, boosted sales
** Avg rating of four analysts on ABOT at "strong buy";
median PT is 31,850 rupees - LSEG data
** Stock gained ~30% in 2024
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))